The scientific impact of the Structural Genomics Consortium: a protein family and ligand-centered approach to medically-relevant human proteins

As many of the structural genomics centers have ended their first phase of operation, it is a good point to evaluate the scientific impact of this endeavour. The Structural Genomics Consortium (SGC), operating from three centers across the Atlantic, investigates human proteins involved in disease processes and proteins from Plasmodium falciparum and related organisms. We present here some of the scientific output of the Oxford node of the SGC, where the target areas include protein kinases, phosphatases, oxidoreductases and other metabolic enzymes, as well as signal transduction proteins. The SGC has aimed to achieve extensive coverage of human gene families with a focus on protein–ligand interactions. The methods employed for effective protein expression, crystallization and structure determination by X-ray crystallography are summarized. In addition to the cumulative impact of accelerated delivery of protein structures, we demonstrate how family coverage, generic screening methodology, and the availability of abundant purified protein samples, allow a level of discovery that is difficult to achieve otherwise. The contribution of NMR to structure determination and protein characterization is discussed. To make this information available to a wide scientific audience, a new tool for disseminating annotated structural information was created that also represents an interactive platform allowing for a continuous update of the annotation by the scientific community.

[1]  M. Yaffe,et al.  A Structural Basis for 14-3-3σ Functional Specificity*♦ , 2005, Journal of Biological Chemistry.

[2]  Ruben Abagyan,et al.  Disseminating structural genomics data to the public: from a data dump to an animated story. , 2006, Trends in biochemical sciences.

[3]  J. Forman-Kay,et al.  Solution structure of a Nedd4 WW domain–ENaC peptide complex , 2001, Nature Structural Biology.

[4]  R. Liddington,et al.  Crystal structure of a PDZ domain , 1996, Nature.

[5]  J. Adamski,et al.  Characterization of Human DHRS6, an Orphan Short Chain Dehydrogenase/Reductase Enzyme , 2006, Journal of Biological Chemistry.

[6]  M. Yaffe,et al.  The Structural Basis for 14-3-3:Phosphopeptide Binding Specificity , 1997, Cell.

[7]  John Kuriyan,et al.  Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.

[8]  Michael B Yaffe,et al.  How do 14‐3‐3 proteins work? – Gatekeeper phosphorylation and the molecular anvil hypothesis , 2002, FEBS letters.

[9]  K. Kavanagh,et al.  Structure of Human Phytanoyl-CoA 2-Hydroxylase Identifies Molecular Mechanisms of Refsum Disease* , 2005, Journal of Biological Chemistry.

[10]  R. Thieringer,et al.  Inhibition of 11β-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role? , 2005, Expert review of cardiovascular therapy.

[11]  O. Fedoroff,et al.  The Structure and Dynamics of Tandem WW Domains in a Negative Regulator of Notch Signaling, Suppressor of Deltex* , 2004, Journal of Biological Chemistry.

[12]  Piero Rinaldo,et al.  Fatty acid oxidation disorders. , 2002, Annual review of physiology.

[13]  S. Knapp,et al.  The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  L. Johnson,et al.  Protein Kinase Inhibitors: Insights into Drug Design from Structure , 2004, Science.

[15]  M. Cooper,et al.  The Role of 11 β-Hydroxysteroid Dehydrogenase in Central Obesity and Osteoporosis , 2000, Endocrine research.

[16]  S. Knapp,et al.  Crystal Structures of the p21-Activated Kinases PAK4, PAK5, and PAK6 Reveal Catalytic Domain Plasticity of Active Group II PAKs , 2007, Structure.

[17]  Steven E Brenner,et al.  The Impact of Structural Genomics: Expectations and Outcomes , 2005, Science.

[18]  Stefan Knapp,et al.  Structure and Regulation of the Human Nek2 Centrosomal Kinase* , 2007, Journal of Biological Chemistry.

[19]  H. Hermeking,et al.  14-3-3 proteins in cell cycle regulation. , 2006, Seminars in cancer biology.

[20]  J Günter Grossmann,et al.  Structural basis for protein–protein interactions in the 14-3-3 protein family , 2006, Proceedings of the National Academy of Sciences.

[21]  P. Cohen Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[22]  L. Cantley,et al.  Recognition of Unique Carboxyl-Terminal Motifs by Distinct PDZ Domains , 1997, Science.

[23]  Stefan Knapp,et al.  Crystal structure of the SOCS2–elongin C–elongin B complex defines a prototypical SOCS box ubiquitin ligase , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Smerdon,et al.  Structure of a 14-3-3 protein and implications for coordination of multiple signalling pathways , 1995, Nature.

[25]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[26]  B. Walker,et al.  11β-Hydroxysteroid dehydrogenase Type 1 as a novel therapeutic target in metabolic and neurodegenerative disease , 2003, Expert opinion on therapeutic targets.

[27]  S. Knapp,et al.  Structural basis of inhibitor specificity of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM-1) kinase. , 2005, Journal of medicinal chemistry.

[28]  F. Young Biochemistry , 1955, The Indian Medical Gazette.

[29]  H. Hermeking,et al.  The crystal structure of the non-liganded 14-3-3σ protein: insights into determinants of isoform specific ligand binding and dimerization , 2005, Cell Research.

[30]  Janet Newman,et al.  Towards rationalization of crystallization screening for small- to medium-sized academic laboratories: the PACT/JCSG+ strategy. , 2005, Acta crystallographica. Section D, Biological crystallography.

[31]  D. Campbell,et al.  14-3-3-affinity purification of over 200 human phosphoproteins reveals new links to regulation of cellular metabolism, proliferation and trafficking. , 2004, The Biochemical journal.

[32]  G. Superti-Furga,et al.  Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.

[33]  D. Bredt,et al.  PDZ domain of neuronal nitric oxide synthase recognizes novel C-terminal peptide sequences , 1997, Nature Biotechnology.

[34]  U. Oppermann Type 1 11beta-hydroxysteroid dehydrogenase as universal drug target in metabolic diseases? , 2006, Endocrine, metabolic & immune disorders drug targets.

[35]  R. Frank Spot-synthesis: an easy technique for the positionally addressable, parallel chemical synthesis on a membrane support , 1992 .

[36]  G J Kleywegt,et al.  Validation of protein crystal structures. , 2000, Acta crystallographica. Section D, Biological crystallography.

[37]  T. Pawson,et al.  Proteomic, Functional, and Domain-Based Analysis of In Vivo 14-3-3 Binding Proteins Involved in Cytoskeletal Regulation and Cellular Organization , 2004, Current Biology.

[38]  M. Bennett,et al.  Inborn Errors of Mitochondrial Fatty Acid Oxidation , 2000, Critical reviews in clinical laboratory sciences.

[39]  William Arbuthnot Sir Lane,et al.  Comprehensive Proteomic Analysis of Interphase and Mitotic 14-3-3-binding Proteins* , 2004, Journal of Biological Chemistry.

[40]  Y. Kato,et al.  Regulation of drug transporters by PDZ adaptor proteins and nuclear receptors. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[41]  Cheryl H Arrowsmith,et al.  Solution NMR in structural genomics. , 2006, Current opinion in structural biology.

[42]  John H. Lewis,et al.  Crystal Structures of a Complexed and Peptide-Free Membrane Protein–Binding Domain: Molecular Basis of Peptide Recognition by PDZ , 1996, Cell.

[43]  M. Vieth,et al.  Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. , 2004, Biochimica et biophysica acta.

[44]  M. Vieth,et al.  Kinomics: characterizing the therapeutically validated kinase space. , 2005, Drug discovery today.

[45]  V. Hu The Cell Cycle , 1994, GWUMC Department of Biochemistry Annual Spring Symposia.

[46]  Victor S. Lobanov,et al.  High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery , 2001 .

[47]  K. Kavanagh,et al.  Structural and biochemical characterization of human orphan DHRS10 reveals a novel cytosolic enzyme with steroid dehydrogenase activity. , 2007, The Biochemical journal.

[48]  A. Wynshaw-Boris,et al.  Role of 14-3-3 proteins in eukaryotic signaling and development. , 2005, Current topics in developmental biology.

[49]  R. Liddington,et al.  Crystal structure of the zeta isoform of the 14-3-3 protein , 1995, Nature.

[50]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[51]  E. Raymond,et al.  New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. , 2006, Seminars in oncology.

[52]  M. Sheng,et al.  PDZ domain proteins of synapses , 2004, Nature Reviews Neuroscience.

[53]  R. Frank The SPOT-synthesis technique. Synthetic peptide arrays on membrane supports--principles and applications. , 2002, Journal of immunological methods.

[54]  P. Nordlund,et al.  Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination , 2006, Proceedings of the National Academy of Sciences.

[55]  L. Guarente,et al.  A Stress Response Pathway Involving Sirtuins, Forkhead and 14-3-3 Proteins , 2006, Cell cycle.

[56]  R. Ghirlando,et al.  Crystal Structure of the 14-3-3ζ:Serotonin N-Acetyltransferase Complex A Role for Scaffolding in Enzyme Regulation , 2001, Cell.

[57]  D. Doyle,et al.  Structure of PICK1 and other PDZ domains obtained with the help of self‐binding C‐terminal extensions , 2007, Protein science : a publication of the Protein Society.

[58]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[59]  Slawomir K. Grzechnik,et al.  Shotgun crystallization strategy for structural genomics: an optimized two-tiered crystallization screen against the Thermotoga maritima proteome. , 2003, Acta crystallographica. Section D, Biological crystallography.

[60]  P. Maček,et al.  pH and temperature-induced molten globule-like denatured states of equinatoxin II: a study by UV-melting, DSC, far- and near-UV CD spectroscopy, and ANS fluorescence. , 1997, Biochemistry.

[61]  R. Rosenfeld Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[62]  J Pohl,et al.  14-3-3ζ Binds a Phosphorylated Raf Peptide and an Unphosphorylated Peptide via Its Conserved Amphipathic Groove* , 1998, The Journal of Biological Chemistry.

[63]  A. McPherson,et al.  Screening and optimization strategies for macromolecular crystal growth. , 1994, Acta crystallographica. Section D, Biological crystallography.